Apyx Medical Corporation
NASDAQ:APYXMedical - Devices
-$0.08 today
- Market cap
- $104.89M
- Beta
- 1.39
- P/E (TTM)
- -19.0
- EPS (TTM)
- -$0.22
Volume 0.19M
Average 0.18M
APYX Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Apyx Medical CorporationNASDAQ: APYX
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables growth accelerates
Q1 FY2026 accounts receivables of $3.95M rose 0.3% year over year, ahead of the -404.9% change in trailing-twelve-month accounts receivables.
Context
- Accounts receivables amounted to 2.5% of revenue in FY2025, down 1.7 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +0.3% holds above the trailing-twelve-month pace of -404.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (1.32M) USD
- Year-over-year change
- +35.2%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.32M) | +35.2% |
| FY2024 | 2024-12-31 | (2.04M) | -151.2% |
| FY2023 | 2023-12-31 | 3.97M | +107.0% |
| FY2022 | 2022-12-31 | 1.92M | +139.1% |
| FY2021 | 2021-12-31 | (4.9M) | — |
Accounts Receivables vs competitors
How APYX compares with its peers on the latest reported figures
- APYX's LTM Mar 2026 accounts receivables of $1.31M is the 5th largest of the 8 companies compared; the peer median is $522K.
- Its year-over-year change of -404.9% is the 6th highest of 8, against a peer median of -16.1%.
- Accounts receivables amounts to 2.3% of revenue for APYX, versus a peer median of 4.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.09M | +162.7% | — | 4.3% | |
| LTM Mar 2026 | $2.97M | +199.2% | -46.9% | 2.4% | |
| LTM Mar 2026 | $2.81M | -16.1% | -17.0% | 3.8% | |
| LTM Mar 2026 | $1.84M | -561.0% | — | 5.4% | |
| LTM Mar 2026 | $1.31M | -404.9% | — | 2.3% | |
| LTM Mar 2026 | $631K | +5158.3% | — | 12.3% | |
| LTM Mar 2026 | $522K | -769.2% | — | — | |
| LTM Mar 2026 | $14K | -80.8% | — | 24.6% | |
| Peer median (excluding APYX) | $522K | -16.1% | -31.9% | 4.8% | |
Competitors are the stored peer set for APYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (15.2M) | (23.28M) | (18.85M) | (23.56M) | (11.11M) |
| Depreciation & Amortization | 903K | 890K | 692K | 599K | 655K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.09M | 6.7M | 5.11M | 4.01M | 2M |
| Change in Working Capital | (1.84M) | (5.22M) | 5.54M | (1.25M) | (1.59M) |
| Accounts Receivables | (4.9M) | 1.92M | 3.97M | (2.04M) | (1.32M) |
| Inventory | (2.86M) | (5.57M) | 1.46M | 2.26M | (1.07M) |
| Accounts Payables | 1.15M | 67K | 25K | (63K) | 355K |
| Other Working Capital | 4.76M | (1.63M) | 88K | (1.41M) | 446K |
| Other Non-Cash Items | 603K | 628K | 2.25M | 2.15M | 2.04M |
| Operating Cash Flow | (10.45M) | (20.28M) | (5.25M) | (18.05M) | (8M) |
| Capital Expenditures | (723K) | (1.01M) | (533K) | (722K) | (1.11M) |
| Acquisitions (Net) | 195K | 0 | 7.41M | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (195K) | 0 | (147K) | 0 | 0 |
| Investing Cash Flow | (723K) | (1.01M) | 6.73M | (722K) | (1.11M) |
| Debt Repayment | (238K) | (148K) | 35.04M | (20K) | (20K) |
| Common Stock Issued | 67K | 365K | 2.72M | 7M | 9.54M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 195K | 0 | (5.59M) | (235K) | 60K |
| Financing Cash Flow | 24K | 217K | 32.17M | 6.75M | 9.58M |
| Effect of Forex Changes | 103K | 395K | (191K) | 113K | (466K) |
| Net Change in Cash | (11.05M) | (20.68M) | 33.46M | (11.91M) | (1K) |
| Free Cash Flow | (11.17M) | (21.29M) | (5.78M) | (18.77M) | (9.12M) |
Apyx Medical Corporation
NASDAQ:APYX
Intrinsic Alpha fair value
Locked
Current Price
$2.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.